TAP Partner News During EHA: June 2022
TAP Partner News During EHA: June 2022
Caribou Biosciences Reports Positive Additional Data from CB-010 Allogeneic CAR-T Cell Therapy Phase 1 ANTLER Trial at the European Hematology Association (EHA) 2022 Hybrid Congress
BERKELEY, Calif., June 10, 2022 - Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the presentation of additional initial clinical data from its ANTLER Phase 1 trial for CB-010 in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). Following a single dose at the initial dose level of CB-010, a 100% complete response (CR) rate (6 of 6 patients) was observed as best response. At 6 months following the single dose of CB-010, 40% of patients remained in CR (2 of 5 patients) as of the May 13, 2022 data cutoff date. The data are being presented at the European Hematology Association (EHA) 2022 Hybrid Congress, being held in Vienna, Austria, June 9-17, 2022.
Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress
Krakow, Poland – June 10, 2022 – Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced updated data from the ongoing Phase 1b dose-escalation study of RVU120 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (HR-MDS) at the Annual European Hematology Association (EHA) 2022 Hybrid Congress, June 9-17 in Vienna, Austria.
X4 Pharmaceuticals to Present Research Data at the 2022 European Hematology Association (EHA) Congress Supporting Mechanism and Market Potential for Mavorixafor
BOSTON, May 16, 2022 - X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with rare immune system disorders, today announced that it will present research data supporting the mechanism and market potential of its lead drug candidate, mavorixafor, as part of three posters at the upcoming European Hematology Association (EHA) congress to be held in Vienna, Austria, June 9-17, 2022.
MorphoSys to Present New Data on Pelabresib at the 2022 European Hematology Association (EHA)
BOSTON, MA, May 12, 2022 - MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced that new data on pelabresib will be presented during the 2022 European Hematology Association Hybrid Congress (EHA 2022) in Vienna, Austria, from June 9 – 12, 2022.
Jazz Pharmaceuticals to Present Data Showcasing Clinical Advancements Across Oncology Portfolio at 2022 EHA Meeting
DUBLIN, May 12, 2022 - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company present abstracts on Vyxeos®/Vyxeos® Liposomal (daunorubicin and cytarabine), also known as JZP351 at the 27th Annual Congress of the European Hematology Association (EHA) from June 9 –12, 2022.
Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
Heidelberg, Germany, May 12, 2022 – Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an upcoming poster presentation demonstrating the cytotoxic potential of its CD123/CD16A-targeting innate cell engager (ICE®) AFM28 at the Annual Meeting of the European Hematology Association (EHA) to be held in Vienna, Austria on June 9 – 12, 2022.